<DOC>
	<DOCNO>NCT02277743</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group study confirm efficacy safety dupilumab monotherapy adult moderate-to-severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Study Dupilumab ( REGN668/SAR231893 ) Monotherapy Administered Adult Patients With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Male female , 18 year old 2 . Chronic AD ( accord American Academy Dermatology Consensus Criteria Eichenfield 2014 ) present least 3 year screen visit 3 . EASI score ≥16 screen baseline visit 4 . IGA score ≥3 ( 0 4 IGA scale , 3 moderate 4 severe ) screen baseline visit 5 . ≥10 % body surface area ( BSA ) AD involvement screen baseline visit 6 . Documented recent history ( within 6 month screen visit ) inadequate response treatment topical medication topical treatment otherwise medically inadvisable ( eg , important side effect safety risk 1 . Participation prior dupilumab clinical study 2 . Treatment investigational drug within 8 week within 5 halflives ( know ) , whichever longer , baseline visit 3 . Having use follow treatment within 4 week baseline visit , condition , opinion investigator , likely require treatment ( ) first 4 week study treatment : Immunosuppressive/ immunomodulating drug ( eg , systemic corticosteroid , cyclosporine , mycophenolatemofetil , IFNγ , Janus kinase inhibitor , azathioprine , methotrexate , etc . ) Phototherapy AD 4 . Treatment topical corticosteroid ( TCS ) topical calcineurin inhibitor ( TCI ) within 1 week baseline visit 5 . Treatment biologics follow : Any celldepleting agent include limited rituximab : within 6 month baseline visit , lymphocyte count return normal , whichever long Other biologics : within 5 halflives ( know ) 16 week prior baseline visit , whichever longer 6 . Regular use ( 2 visit per week ) tan booth/ parlor within 4 week screen visit 7 . Planned anticipated use prohibit medication procedure study treatment 8 . Treatment live ( attenuate ) vaccine within 12 week baseline visit 9 . Active chronic acute infection require treatment systemic antibiotic , antiviral , antiparasitics , antiprotozoal , antifungal within 2 week baseline visit , superficial skin infection within 1 week baseline visit . NOTE : patient may rescreened infection resolve 10 . Known suspected history immunosuppression , include history invasive opportunistic infection ( eg , tuberculosis [ TB ] , histoplasmosis , listeriosis , coccidioidomycosis , pneumocystosis , aspergillosis ) despite infection resolution : unusually frequent , recurrent , prolonged infection , per investigator judgment 11 . History human immunodeficiency virus ( HIV ) infection positive HIV serology screen 12 . Positive hepatitis B surface antigen ( HBsAg ) hepatitis C antibody screen visit 13 . Patient member investigational team his/her immediate family 14 . Pregnant breastfeed woman , woman plan become pregnant breastfeed study 15 . Women unwilling use adequate birth control , reproductive potential sexually active . Note : The information list intend contain consideration relevant patient 's potential participation clinical trial therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>